Impact of temporalis muscle thickness in elderly patients with newly diagnosed glioblastoma treated with radio or radio-chemotherapy

Radiol Med. 2022 Aug;127(8):919-924. doi: 10.1007/s11547-022-01524-2. Epub 2022 Jul 18.

Abstract

Background: There is an unmet need for new biomarkers able to predict both the outcomes of up-front therapy and the compliance of elderly patients diagnosed with glioblastoma. For this purpose, temporal muscle thickness is a promising tool to be investigated.

Methods: Data from 52 glioblastoma patients older than 65 years, treated with post-operative radio or radio-chemotherapy and referred to Pisa University Hospital, were retrieved. The thickness of temporal muscle (TMT) was divided into quartiles and correlated with overall survival (Our primary endpoint). Survival curves were calculated using Kaplan-Meier method, and log-rank test was used to evaluate the differences between curves.

Results: Patients in the lower quartile of TMT, with TMT thinner than 7 mm, have survived longer; both univariate and multivariate analyses showed a statistically significant correlation between TMT and overall survival (P = 0.012 and P = 0.003, respectively).

Conclusion: Future prospective and more extensive studies focused on elderly glioblastoma patients are needed to confirm the role of TMT as prognostic value on OS and to help explaining this association.

Keywords: Elderly patients; Elderly patients with glioblastoma; Geriatric oncology sarcopenia; Glioblastoma; Glioblastoma biomarkers; Radiotherapy; Temporalis thickness.

MeSH terms

  • Aged
  • Brain Neoplasms* / drug therapy
  • Brain Neoplasms* / therapy
  • Chemoradiotherapy
  • Glioblastoma* / diagnostic imaging
  • Glioblastoma* / drug therapy
  • Humans
  • Prognosis
  • Retrospective Studies
  • Temporal Muscle